Galapagos NV (NASDAQ:GLPG) shares gapped up prior to trading on Tuesday . The stock had previously closed at $54.18, but opened at $54.51. Galapagos NV shares last traded at $55.13, with a volume of 23,112 shares traded.

GLPG has been the subject of several research analyst reports. Zacks Investment Research cut shares of Galapagos NV from a “hold” rating to a “sell” rating in a research report on Thursday, April 28th. Cowen and Company restated a “buy” rating on shares of Galapagos NV in a research report on Saturday, April 30th. Morgan Stanley dropped their price objective on shares of Galapagos NV from $92.00 to $89.00 and set an “overweight” rating for the company in a research report on Monday, May 2nd. Finally, Credit Suisse Group AG restated a “hold” rating and issued a $48.00 price objective on shares of Galapagos NV in a research report on Friday, June 17th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of €65.50 ($74.43).

The firm’s market capitalization is $2.49 billion. The company’s 50 day moving average is $53.91 and its 200 day moving average is $49.20.

Galapagos NV is a Belgium-based biotechnology company. The Company’s activities are divided into two operating divisions: Research and Development (R & D) and Services. The R & D division is engaged in the discovery and development of small molecules. The Services division, offers target-to-drug discovery products and services to pharmaceutical and biotechnology companies and to patient foundations, encompassing target discovery and validation, screening and drug discovery through to delivery of pre-clinical candidates.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.